Latest Gestational Trophoblastic Disease Companies Updates:
Roche Holding AG (Switzerland) Presented positive Phase 2 data demonstrating the potential of their anti-PD-1 antibody, atezolizumab, in combination with bevacizumab for treating high-risk gestational trophoblastic neoplasia (GTN).Partnered with research institutions to investigate the use of immunotherapy in GTD treatment and improve outcomes for patients with aggressive forms.
Merck & Co., Received FDA approval for their pevonimod, a novel oral therapy targeting the PI3K/AKT pathway, for treating recurrent gestational choriocarcinoma.Collaborated with healthcare providers to expand access to pevonimod and provide support for GTD patients undergoing treatment.
Genentech, Launched a clinical trial evaluating the safety and efficacy of their anti-angiogenic drug, bevacizumab, in combination with chemotherapy for treating high-risk GTN.Focused on developing and evaluating new treatment options with less severe side effects compared to traditional chemotherapy in GTD patients.
NantCancer (US) Initiated a Phase 2 clinical trial investigating their targeted therapy, ONC212, in combination with pembrolizumab for treating metastatic gestational trophoblastic disease.Emphasized the importance of personalized treatment approaches based on individual patient characteristics and tumor molecular profiles.
American Cancer Society (ACS)Updated their GTD patient education materials and launched a new awareness campaign to empower women with information about early detection and treatment options.Partnered with other patient advocacy groups to provide support and resources for GTD patients and their families.
List of Gestational Trophoblastic Disease Key companies in the market
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Antares Pharma
- Mylan N.V.
- Novartis AG
- BP Pharmaceuticals Laboratories Company
- Fresenius Kabi AG
- Accord Healthcare, Inc.
- Eli Lilly and Company
- Sanofi
- Bayer AG
- Amgen Inc.